DIRS.INFO The most relevant business & tech news

☆ 'This is the mental health moment': Innovation and M&A are helping to boost these stocks to new heights
▼ + stars: | 2024-02-19 | by ( Michelle Fox | ) www.cnbc.com time to read: +14 min

There's been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Attention to a long-time crisis The mental health crisis is nothing new. However, there has also been a growing awareness and acceptance of mental health illnesses over the past decade, said Canaccord Genuity analyst Richard Close. "There's been recognition that mental health has a significant impact on a person's overall health," he said. "This is the mental health moment," said Dr. Ken Duckworth, NAMI's chief medical officer and author of "You Are Not Alone: The NAMI Guide to Mental Health."

Persons: There's, Covid, Peter Micca, AbbVie, Emraclidine, Myers Squibb, Karuna, Marc Goodman, Canaccord, Richard Close, MacKenzie Scott, Ken Duckworth, NAMI, Deloitte's Micca, William Blair, Myles Minter, Minter, Auvelity, Leerink's Goodman, Ashwani Verma, Verma, Goodman, BioHaven, Cerevel, Neumora, tardive, David Song, BetterHelp, psychedelics Johnson, Johnson, Spravato, Blair's Minter, Axsome, Micca, Michael Bloom Organizations: Institute for Health Metrics, Deloitte, Cerevel Therapeutics, Karuna Therapeutics, Bristol Myers, Leerink Partners, Centers for Disease Control, National Alliance, Mental, Mental Health, Wall Street, Therapeutics, Neumora Therapeutics, UBS, Karuna, Cellular Therapies, Xenon Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals, Tema Neuroscience, Axsome Therapeutics, Acadia Healthcare, BetterHelp, CNBC, pharma, Cellular Locations: Covid, Bristol, XEN1101, Acadia, Tema

☆ This startup is opening a mental health clinic that offers ketamine therapy. We got an exclusive look at the pitch deck it used to raise $5.4 million.
▼ + stars: | 2024-01-25 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +5 min

Read previewVenture investment in mental health startups exploded in 2021. Being Health, an integrated mental healthcare company, is opening its first location, located in Manhattan's Financial District. Services like ketamine infusions and acupuncture will have to be administered in person, but others, like nutrition counseling, will have a virtual option, Sharma said. "When it comes to this novel approach to addressing mental health, you can't do that with telehealth." See the 17-slide pitch deck mental health startup Being Health used to raise $5.4 million in seed funding.

Persons: —, Allie Sharma's, Sharma, Janssen, Haim Dabah, Dabah Organizations: Service, Business, Financial, HDS, FDA, Janssen Pharmaceuticals, Being Health, Services, HDS Capital Locations: New York, New York City

☆ Matthew Perry's death means hard questions for the ketamine movement
▼ + stars: | 2023-12-20 | by ( Anna Silman | ) www.businessinsider.com time to read: +10 min

AdvertisementWhen Charles Patti read that ketamine had been a major factor in the "Friends" star Matthew Perry's death, his heart sank. AdvertisementMultiple researchers told Business Insider that labeling ketamine as the sole cause of Perry's death is misleading. "Matthew Perry's ketamine overdose should be a lesson in expanded use of the dangerous drug," declared The New York Post. There's no data on how many people go from receiving ketamine treatment in clinics to using it without a prescription. Herzberg, the historian, said he's not particularly worried about Perry's death causing a moral panic.

Persons: Matthew Perry, —, Charles Patti, Matthew Perry's, Patti, Perry, Matthew, Joanna Moncrieff, Ryan Marino, Marilyn Monroe's, David Herzberg, Len Bias, Gerard Sanacora, it's, Chrissy Teigen, Elon Musk, We've, Herzberg, wasn't, Sanacora, I've, Sandhya Prashad, wouldn't, Keith Trujillo, Trujillo, he's Organizations: Service, Los, Business, New York, University of Buffalo, Yale, FDA, American Society, Physicians, Psychotherapists Locations: Florida, Los Angeles County, British, Swiss

Prescriptions for ketamine have soared in recent years, driven by for-profit clinics and telehealth services offering the medication as a treatment for pain, depression, anxiety and other conditions. With its recent adoption for pain, patients are increasingly encountering those same effects. Ketamine targets a brain chemical messenger called glutamate, which is thought to play a role in both pain and depression. “We want patients to disassociate or feel separate from their pain, depression or anxiety,” said Dr. David Mahjoubi, owner of Ketamine Healing Clinic in Los Angeles. But the experts found “weak or no evidence” for ketamine in many more conditions, including back pain, migraines, fibromyalgia and cancer pain.

Persons: “, ”, Padma Gulur, Gulur, Daniel Bass, Bass, ” Bass, David Mahjoubi, they’re, Eric Schwenk, Thomas, “ There’s, Johnson, Samuel Wilkinson, Caleb Alexander, Matthew Perrone Organizations: WASHINGTON, Duke University, Duke, Food and Drug Administration, FDA, Thomas Jefferson University, Epic Research, Johnson, Drug Enforcement, Yale University, Johns Hopkins University, Twitter, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: As, U.S, Southgate , Kentucky, Los Angeles, anesthesiology, Massachusetts

☆ J&J's strong quarter was amplified by new details around its big Kenvue consumer unit stake
▼ + stars: | 2023-07-20 | by ( Zev Fima | ) www.cnbc.com time to read: +12 min

Johnson & Johnson (JNJ) reported strong second - quarter profit and revenue before the opening bell Thursday, with better-than-expected results both domestically and internationally, as well as across all major operating segments. It's possible that J & J management will offer up Kenvue shares at a discount to market value. Regardless, arbitrage isn't our game and we want to be invested in J & J for the long term. The only change — since J & J owns 89.6% of Kenvue — is that 10.4% of earnings generated since Kevnue went public in early May to the end of the quarter are no longer attributed to J & J. A Johnson & Johnson building is shown in Irvine, California.

Persons: Johnson, —, Kevnue, J, J's, prioritization, Jim Cramer's, Jim Cramer, Jim, Mike Blake Organizations: Dow, Pharmaceutical, Management, J's, Johnson, J, Consumer, Consumer Health, Pharmaceutical Pharmaceutical, CNBC, & $ Locations: Kenvue, JNJ, KVUE, Spravato, Irvine , California

☆ How a family's struggle to help their son gave rise to controversial $400 million psychedelics giant Compass Pathways
▼ + stars: | 2023-02-15 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +18 min

Today, Compass Pathways, the for-profit company they launched in 2016, is a Nasdaq-listed firm worth about $400 million. Compass Pathways Show lessIt could also boost the dozens of psychedelics companies inspired by Compass that have been formed in recent years. Insider spoke with more than a dozen industry participants to chart the rise of Compass Pathways and its role in the psychedelics boom. He recalled the 2018 Quartz article that detailed the growing alarm around Compass Pathways' "magic mushroom monopoly." Were it not for his decision to take a break from college, and his parents' efforts to find a treatment, Compass Pathways might not exist.

☆ Ketamine is being sold as a depression wonder drug. For some, it's making everything worse.
▼ + stars: | 2023-01-25 | by ( Anna Silman | ) www.businessinsider.com time to read: +42 min

The infusions at the ketamine clinic in his West Texas hometown were a Christmas gift from his grandmother. About five years ago, more and more of my friends started using ketamine recreationally. IV ketamine treatment centers charging $400 to $2,000 an infusion popped up all over the country. "Ketamine used as directed in an appropriate clinical setting very rarely leads to any dependence," Mindbloom says on its website. Like Nadia, most of the people I interviewed said when they started using ketamine, they didn't think it was possible to become dependent on it.

☆ Johnson & Johnson deserves more credit for another healthy quarter and strong guidance
▼ + stars: | 2023-01-24 | by ( Jeff Marks | ) www.cnbc.com time to read: +6 min

Johnson & Johnson (JNJ) posted another solid quarter of healthy growth — and another productive year of free-cash-flow generation — despite a slight miss on sales. On an adjusted operational basis, which excludes the impact of acquisitions and divestitures and currency, sales rose 0.8%. But the new year has been tough on pharmaceutical stocks and almost all of health care, including JNJ stock, which is down 6% year to date. Johnson & Johnson forecasts adjusted EPS on an operational basis to grow 2.5% to 4.5%, which at a midpoint of $10.50 compares favorably to the consensus of $10.33. Its addition to the MedTech division is expected to help accelerate sales growth this year.

☆ The CEO of a psychedelics giant that just suffered a big setback lays out why investors should bet on his long-term vision
▼ + stars: | 2023-01-11 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +4 min

PCN-101, a ketamine-based treatment, failed to help people with treatment-resistant depression. CEO Florian Brand said he thinks investors should bet on the company's long-term vision. Florian Brand, the CEO of the psychedelics giant Atai Life Sciences, said investors should look past the company's recent failed clinical trial and bet on his long-term vision for the company. On January 6, Atai announced that a highly anticipated trial of a ketamine-based depression treatment failed to meet its goals. The company also owns a large stake in the psychedelics company Compass Pathways, which is currently in late-stage trials to develop psilocybin, the psychoactive ingredient found in magic mushrooms, for treatment-resistant depression.

☆ The stock of psychedelics giant Atai is tumbling after a treatment failed to help patients in a trial
▼ + stars: | 2023-01-06 | by ( Sarah Braner | ) www.businessinsider.com time to read: +2 min

Atai Life Sciences said that its ketamine therapy failed to help patients in a trial. Patients who received ketamine didn't fare better than those who got the placebo, Atai said in a press release. Ketamine, a surgical anesthetic, is currently being tested as a possible treatment option for patients with severe depression that has not responded to other kinds of therapy. According to Insider's tracker, there are four other mid-stage trials of ketamine underway for conditions such as treatment-resistant depression and alcohol-use disorder. In the Perception Neuroscience trial, 102 patients with treatment-resistant depression were given 60mg of PCN-101, 30mg of the therapy, or a placebo group.

Instead, this ketamine clinic feels like an oasis of zen, strewn with twinkle lights, lush greenery and comfy meditation pillows. Chere Scythes, right, listens to guided meditation during a ketamine session at Field Trip Health in New York City. “And so many of these clinics don’t have mental health professionals staffing them. When those mental health concerns pop up, they may not be equipped to respond appropriately.”Ketamine also isn’t a cure-all. “That deep dark depressive cloud started to lift.”In combination with her antidepressants, she has continued the ketamine treatments and now gets one every five weeks.

☆ Compass Pathways' new CEO says data from his firm's upcoming clinical trial could finally persuade Big Pharma to jump into the psychedelics industry
▼ + stars: | 2022-11-09 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +3 min

Compass Pathways is set to start its biggest clinical trial yet by the end of this year. But that may soon change as more data around the effectiveness of psychedelics as treatments emerges, according to Kabir Nath, the new CEO of the psychedelics company Compass Pathways. He joined Compass Pathways from the Japanese pharmaceutical company Otsuka in August and led Otsuka's investment into Compass Pathways during the company's $80 million Series B round in 2019. At the time of Otsuka's initial investment into Compass Pathways, the psychedelics industry was relatively new and the potential around such treatments was still not well known. In 2019, the Food and Drug Administration approved a ketamine-based treatment called Spravato for treatment-resistant depression that was developed by Johnson & Johnson's Janssen.

Search resuls for: "Spravato"

12 mentions found